Silence Says New Patents Key to Licensing Deals, Keeps Eye on R&D Collaborations

As RNAi drug candidates move through pipelines and information about their structures becomes available, Silence expects to find that "a number" of them incorporate modifications covered by its IP.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories